Enhancing Outcomes and Reducing Treatment Burden with Advanced Therapies in Neovascular AMD and DME : Episode 10
Safety Profile of New Therapies
Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.
Video content above is prompted by the following:
- Based on the clinical trial data, how do you view the safety profiles of faricimab and aflibercept 8 mg?
- Does the long-term safety profile of aflibercept 2 mg increase your confidence in the safety of aflibercept 8 mg?
- Does the increased volume of aflibercept 8 mg raise concerns about the potential for elevated intraocular pressure? How do you evaluate and address this in clinical practice?
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
